Teclistamab in Relapsed or Refractory Multiple Myeloma

Philippe Moreau, Alfred L. Garfall, Niels W.C.J. van de Donk, +31

New England Journal of Medicine

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, +16

The Lancet Oncology

Hematological MalignancyOncologyRelapsed Multiple MyelomaHematologyMyeloid Neoplasia +5

Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma

Ajai Chari, Monique C. Minnema, Jesús G. Berdeja, +17

New England Journal of Medicine

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, +18

The Lancet

Hematological MalignancyMedicineMalignant Blood DisorderImmunologyTumor Immunity +6

Pharmacokinetic, Pharmacodynamic and Covariate Analysis of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma

Philippe Moreau, Ievgenii Karamanesht, Maryna Kyselyova, +14

Clinical Pharmacokinetics

Hematological MalignancyOncologyRelapsed Multiple MyelomaMedicineMalignant Blood Disorder +4

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Alfred L. Garfall, Saad Z. Usmani, María‐Victoria Mateos, +14

Blood

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, Jesús G. Berdeja, Albert Oriol, +12

Blood

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Krishnan, Monique C. Minnema, Jesús G. Berdeja, +14

Blood

Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma

Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, +14

Blood Advances

Sbcma LevelsImmunologyImmune RegulationPathologyImmune System +18

Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole

Chirag Patel, Li Li, Suzette Girgis, +3

Clinical Pharmacology Advances and Applications